Trial Profile
Managed Access Program (MAP) to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer Resistant or Refractory to Available Treatment Options
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary)
- Indications Advanced breast cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 13 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Oct 2018 New trial record